Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 3
2005 1
2006 2
2008 3
2009 3
2010 4
2011 4
2013 3
2014 4
2015 2
2016 4
2017 1
2018 6
2019 5
2020 8
2021 11
2022 4
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Martino EA, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pompa A, Vincelli D, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Ferretti E, Bertuglia G, Nappi D, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P. Gentile M, et al. Among authors: rizzi r. Haematologica. 2024 Jan 1;109(1):245-255. doi: 10.3324/haematol.2023.283251. Haematologica. 2024. PMID: 37439329 Free PMC article.
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
Sgherza N, Curci P, Rizzi R, Larocca AMV, Vimercati L, Tafuri S, Chironna M, Musto P. Sgherza N, et al. Among authors: rizzi r. Mediterr J Hematol Infect Dis. 2023 Jan 1;15(1):e2023011. doi: 10.4084/MJHID.2023.011. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 36660353 Free PMC article. No abstract available.
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance.
Sgherza N, Di Gennaro D, Curci P, Rizzi R, Roccotelli D, Croce M, Avantaggiato M, Ruga L, Strafella V, Vitucci A, Palma A, Russo Rossi AV, Troiano T, Larocca AMV, Chironna M, Tafuri S, Albano F, Musto P. Sgherza N, et al. Among authors: rizzi r. Hemasphere. 2022 Nov 9;6(12):e800. doi: 10.1097/HS9.0000000000000800. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36382051 Free PMC article. No abstract available.
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma.
Sgherza N, Curci P, Rizzi R, Attolico I, Loconsole D, Mestice A, Chironna M, Musto P. Sgherza N, et al. Among authors: rizzi r. Blood Cancer J. 2021 Dec 14;11(12):201. doi: 10.1038/s41408-021-00597-y. Blood Cancer J. 2021. PMID: 34907155 Free PMC article. No abstract available.
68 results